[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"choroideremia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:choroideremia":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,96,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":54,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100242565","inherited-retinal-degenerative-disease-registry-100242565",false,"NCT02435940","Inherited Retinal Degenerative Disease Registry","Foundation Fighting Blindness My Retina Tracker Registry","MRTR","Inclusion Criteria:\n\n* Diagnosed with an inherited retinal degenerative disease OR\n\nExclusion Criteria:\n\n* Glaucoma only\n* Diabetic retinopathy only\n* Non-retinal disease\n* Not heritable retinal disease",true,"ALL",{"count":20,"type":21},20000,"ESTIMATED","20 Years","OBSERVATIONAL","The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by the Foundation. It is a patient-initiated registry accessible via a secure on-line portal at www.MyRetinaTracker.org. Affected individuals who register are guided to create a profile that captures their perspective on their retinal disease and its progress; family history; genetic testing results; preventive measures; general health and interest in participation in research studies. The participants may also choose to ask their clinician to add clinical measurements and results at each clinical visit. Participants are urged to update the information regularly to create longitudinal records of their disease, from their own perspective, and their clinical progress. The overall goals of the Registry are: to better understand the diversity within the inherited retinal degenerative diseases; to understand the prevalence of the different diseases and gene variants; to assist in the establishment of genotype-phenotype relationships; to help understand the natural history of the diseases; to help accelerate research and development of clinical trials for treatments; and to provide a tool to investigators that can assist with recruitment for research studies and clinical trials.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Eye Diseases Hereditary","Retinal Disease","Achromatopsia","Bardet-Biedl Syndrome","Bassen-Kornzweig Syndrome","Batten Disease","Best Disease","Choroidal Dystrophy","Choroideremia","Cone Dystrophy","Cone-Rod Dystrophy","Congenital Stationary Night Blindness","Enhanced S-Cone Syndrome","Fundus Albipunctatus","Goldmann-Favre Syndrome","Gyrate Atrophy","Juvenile Macular Degeneration","Kearns-Sayre Syndrome","Leber Congenital Amaurosis","Refsum Syndrome","Retinitis Pigmentosa","Retinitis Punctata Albescens","Retinoschisis","Rod-Cone Dystrophy","Rod Dystrophy","Rod Monochromacy","Stargardt Disease","Usher Syndrome",[55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82],"inherited retinal degenerative disease","retinitis pigmentosa","Usher","Leber","Bardet-Biedl","Batten","Best","cone dystrophy","cone-rod dystrophy","choroideremia","congenital night blindness","enhanced s-cone","cone monochromacy","Goldmann-Favre","Kearns-Sayre","Refsum","retinoschisis","rod-cone dystrophy","rod dystrophy","rod monochromacy","Sorsby pseudoinflammatory dystrophy","stargardt","achromatopsia","juvenile inherited macular degeneration","cone dichromacy","cone trichromacy","Charcot-Marie-Tooth","albipunctate dystrophy","RECRUITING","2026-05-18",{"date":86,"type":87},"2026-05-19","ACTUAL",{"date":89,"type":4},"2014-06",{"date":91,"type":21},"2037-06",{"name":93,"class":94},"Foundation Fighting Blindness","OTHER",1,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":17,"sex":18,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":106,"conditions":107,"keywords":111,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":95},"100198971","high-resolution-retinal-imaging-100198971","NCT01866371","High Resolution Retinal Imaging","AOSLO","Inclusion Criteria:\n\n* Males or females age 7 years or older.\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent. Child subjects age 7-17 must give assent.\n* Reasonable compliance with an imaging protocol as determined by the study personnel.\n\nExclusion Criteria:\n\n* Individuals that are at risk to acute glaucoma.\n* Individuals that are photophobic and experience adverse psychological reactions to flashes of light.\n* Ocular opacities, high refractive error, and high frequency of nystagmus as determined by the study team.","7 Years",{"count":105,"type":21},600,"Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disease. This protocol uses an adaptive optics scanning laser ophthalmoscope (AOSLO) to image the normal and diseased retina with individual cellular resolution non-invasively. The primary objective of this study is to obtain and analyze high-resolution images of the retina, in particular by imaging the cone photoreceptor mosaic, the retinal vasculature and other retinal layers. The study design will involve case-control studies, where cases are followed over time. Subjects age 7 and older may be invited to participate. The main research procedure involves retinal imaging with the AOSLO. The primary endpoint is the observation of differences in retinal images between subjects with and without retinal diseases. These changes will be quantified by examining the cell density, size, spacing and regularity of the cone photoreceptor mosaic, as well as examining the differences between other retinal layers.",[108,46,109,34,110],"Stargardts","Age-related Macular Degeneration","Geographic Atrophy",[112,113,114],"Retina","imaging","retinal degeneration","2026-04-28",{"date":117,"type":87},"2026-05-05",{"date":119,"type":4},"2013-05",{"date":121,"type":21},"2031-12",{"name":123,"class":94},"University of Pennsylvania",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":18,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":95},"100544926","observational-study-to-assess-endpoint-operational-feasibility--measurement-properties-in-patients-with-retinal-degeneration-100544926","NCT06375239","Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F70 and HM in at least one eye as tested with clinic-based visual acuity method\n* Reasonably fluent in English\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient","18 Years",{"count":133,"type":21},120,"The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.\n\nThe mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.\n\nThe VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.",[46,34,136,52,137,138,139],"Stargardt Macular Dystrophy","Geographic Atrophy from Age-related Macular Degeneration","X-lined Retinoschisis","Retinal Dystrophies","2025-01-06",{"date":142,"type":87},"2025-01-08",{"date":144,"type":87},"2024-04-05",{"date":146,"type":21},"2026-04-30",{"name":148,"class":149},"Ray Therapeutics, Inc.","INDUSTRY"]